title: [New disease-modifying and symptomatic therapies for multiple sclerosis].
authors.affiliation: Klinische Forschungsgruppe für MS und Neuroimmunologie, Neurologische Universitätsklinik, Julius-Maximilians-Universität Würzburg.
authors.forename: Gesa
authors.initials: G
authors.lastname: Weise
authors.forename: Mathias
authors.initials: M
authors.lastname: Buttmann
mesh_terms: D015761:4-Aminopyridine / Q000009:adverse effects / Q000627:therapeutic use; D002186:Cannabinoids / Q000009:adverse effects / Q000627:therapeutic use; D003299:Cooperative Behavior; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D033183:Interdisciplinary Communication; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy*; D011409:Propylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D002186:Cannabinoids; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D015761:4-Aminopyridine; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine